Filed by Pfizer Inc.
Pursuant to Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934, as amended
Subject Company: Pfizer Inc.
(Commission File No. 001-03619)
The following communication is being filed in connection with the
proposed business combination between Mylan N.V. and Upjohn, Pfizer Inc.s off-patent branded and generic established medicines business.
The following are excerpts from the transcript of Pfizer Inc.s first quarter earnings call, held on April 28, 2020.
Corporate Participants
Albert Bourla
Pfizer Inc. Chairman of the Board & CEO
Angela Hwang Pfizer Inc. Group President of Biopharmaceuticals Group
Charles E. Triano Pfizer Inc. SVP of IR
Frank
A. DAmelio Pfizer Inc. CFO & EVP of Global Supply & Business Operations
John D. Young Pfizer Inc. Group
President & Chief Business Officer
Mikael Dolsten Pfizer Inc. Chief Scientific Officer and President of Worldwide Research,
Development & Medical
Conference Call Participants
Andrew Simon Baum Citigroup Inc, Research Division Global Head of Healthcare Research and MD
Carter Lewis Gould Barclays Bank PLC, Research Division Senior Analyst
David Reed Risinger Morgan Stanley, Research Division MD in Equity Research and United States Pharmaceuticals Analyst
Louise Alesandra Chen Cantor Fitzgerald & Co., Research Division Senior Research Analyst & MD
Navin Cyriac Jacob UBS Investment Bank, Research Division Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Randall S. Stanicky RBC Capital Markets, Research Division MD of Global Equity Research & Lead Analyst
Stephen Michael Scala Cowen and Company, LLC, Research Division MD & Senior Research Analyst
Terence C. Flynn Goldman Sachs Group Inc., Research Division MD
Timothy Minton Anderson Wolfe Research, LLC MD of Equity Research
Umer Raffat Evercore ISI Institutional Equities, Research Division Senior MD & Senior Analyst of Equity Research
Vamil Kishore Divan Mizuho Securities USA LLC, Research Division MD
PRESENTATION
Operator
Good day, everyone, and welcome to Pfizers First Quarter 2020 Earnings Conference Call. Todays call is being recorded. At this time, I would like
to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.
Charles E. Triano Pfizer
Inc. SVP of IR
Thank you, operator. Good morning, everyone, and thanks for joining us today to review Pfizers first quarter 2020 financial
results, our reaffirmed full year 2020 financial guidance, Pfizers role in helping find solutions for the COVID-19 pandemic as well as other relevant business topics.
As usual, Im joined today by our Chairman and CEO, Albert Bourla; Frank DAmelio, our CFO; Mikael Dolsten, President of Worldwide Research and
Development; Angela Hwang, Group President, Pfizer Biopharmaceuticals Group; John Young, our Chief Business Officer; and Doug Lankler, our General Counsel.
The slides that will be presented on this call were posted to our website earlier this morning and are available at pfizer.com/investors. Youll see here
on this slide that covers our legal disclosures. Albert and Frank will now make prepared remarks, and then we will move to a question-and-answer session. With that,
Ill now turn the call over to Albert Bourla. Albert?